

QUESTION

I am writing to you today to request information relating to Non-Oral Anti Coagulants (NOACs).

- 1.) In your trust how many patients in the last 3* months have been treated for NVAf (Non-Valvular Atrial Fibrillation), with the drugs below:

Apixaban
Dabigatran
Edoxaban
Rivaroxaban
Warfarin

- 2.) How many patients in the last 3* months have been treated for DVT (Deep Vein Thrombosis), with the drugs below:

Apixaban
Dabigatran
Edoxaban
Rivaroxaban
Warfarin
Heparin

- 3.) How many patients in the last 3* months have been treated for PE (Pulmonary Embolism), with the drugs below:

Apixaban
Dabigatran
Edoxaban
Rivaroxaban
Warfarin
Heparin

- 4.) How many patients in the last 3* months have been treated for the prevention of recurrent DVT (Deep Vein Thrombosis) or prevention of recurrent PE (Pulmonary Embolism) with the drugs below:

Apixaban
Dabigatran

Edoxaban
Rivaroxaban
Warfarin

RESPONSE:

1. Please see below
2. Please see below
3. Please see below
4. Number of unique patients dispensed the following drugs January 2018 – March 2018 inclusive

Apixaban – 365 patients
Dabigatran – 17 patients
Edoxaban – 37 patients
Rivaroxaban – 205 patients
Warfarin – 71 patients

Please note we are unable to provide a breakdown of treatment each patient received the drug for.

ATTACHMENT: No